| Business Summary | | SpectRx,
Inc.
is
a
specialty
point-of-care
medical
diagnostics
company
that
employs
biophotonic
technologies
to
provide
painless,
non-invasive
and
minimally
invasive
alternatives
to
blood
and
tissue
sampling
procedures.
Biophotonic
technology
is
the
use
of
light
and
other
forms
of
energy
to
access
the
human
body
to
diagnose
and
monitor
disease.
The
Company
has
developed
a
product
that
provides
a
non-invasive
alternative
to
the
conventional
blood
test
for
detecting
and
monitoring
infant
jaundice.
The
Company
is
also
developing
products
that
it
believes
will
provide
less
invasive
and
painless
alternatives
to
products
that
are
currently
available
for
conventional
diabetes
detection,
glucose
monitoring
and
cancer
detection. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | SPRX
is
engaged
in
the
research
and
development
of
products
that
offer
less
invasive
and
painless
alternatives
to
blood
tests
currently
used
for
glucose
monitoring,
diabetes
screening
and
infant
jaundice.
For
the
six
months
ended
6/30/01,
revenues
fell
33%
to
$1.3
million.
Net
loss
applicable
to
Common
decreased
4%
to
$3.8
million.
Results
reflect
reduced
collaborative
agreement
revenues,
offset
by
lower
research
and
development
expenses. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Mark Samuels, 42 Chairman,
CEO | $286K | $0.6K | Keith Ignotz, 53 Pres
and COO | 224K | -- | Thomas Muller, Jr., 59 CFO,
Exec. VP, Sec. | 202K | -- | Robert Rothfritz, 51 VP
of Operations | -- | -- | Richard Fowler, 44 VP
of Technology Assessment | 131K | -- | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|